Rabbit Polyclonal Phospho-Smad3 (S204) antibody (STJ90523)


Reactivity: Human, Mouse, Rat
Applications: WB, IHC, IF, ELISA
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Rabbit Polyclonal Phospho-Smad3 (S204) antibody (STJ90523)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, IHC, IF, ELISA

Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:20000;

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for Smad3 (phospho Ser204) Polyclonal Antibody.

Alternative names:

Check alternative names for the antibody


SMAD3 antibody, MADH3 antibody,|DKFZP586N0721 antibody|SMAD 3 antibody|SMAD antibody|SMAD family member 3 antibody|SMAD, mothers against DPP homolog 3 antibody|Smad3 antibody|SMAD3_HUMAN antibody|Anti-Smad3 antibody [EP568Y] (ab40854)
SCBT cat No: sc-11769|sc-130218|sc-514317|sc-165305|sc-515132|sc-74864|sc-390878|sc-100454|sc-100455|sc-71790|sc-56746|



Smad3 (phospho Ser204) Polyclonal Antibody

Catalogue No.



Human, Mouse, Rat


Phospho-Smad3 (S204) Polyclonal Antibody detects endogenous levels of Smad3 protein only when phosphorylated at S204.


Synthesized phospho-peptide derived from Smad3 (phospho Ser204) at AA range 140-220





Recommended dilution

WB 1:500-1:2000; IHC 1:100-1:300; IF 1:200-1:1000; ELISA 1:20000;







Molecular weight

48 kDa


Smad3 (phospho Ser204) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.


1 mg/ml


Smad3 (phospho Ser204) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.


-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

Mothers against decapentaplegic homolog 3 antibody, MAD homolog 3 antibody, Mad3 antibody, Mothers against DPP homolog 3 antibody, hMAD-3 antibody, JV15-2 antibody, SMAD family member 3 antibody, SMAD 3 antibody, Smad3 antibody, hSMAD3 antibody

Database links

Human UniProt/Swiss-Prot:P84022;Mouse UniPort/Swiss-Prot: Q8BUN5;Rat UniProt/Swiss-Port: P84025;Human Entrez Gene: 4088;Mouse Entrez Gene: 17127;Rat Entrez Gene: Rn.10636

Protein names

Mothers against decapentaplegic homolog 3 , MAD homolog 3 , Mad3 , Mothers against DPP homolog 3 , hMAD-3 , JV15-2 , SMAD family member 3 , SMAD 3 , Smad3 , hSMAD3

Protein function

Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.

Involvement in disease

Colorectal cancer (CRC) [MIM:114500]: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history. . Note: The disease may be caused by mutations affecting the gene represented in this entry.; Loeys-Dietz syndrome 3 (LDS3) [MIM:613795]: An aortic aneurysm syndrome with widespread systemic involvement. The disorder is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Patients with LDS3 also manifest early-onset osteoarthritis. They lack craniosynostosis and mental retardation. . Note: The disease is caused by mutations affecting the gene represented in this entry. SMAD3 mutations have been reported to be also associated with thoracic aortic aneurysms and dissection (TAAD) (PubMed:21778426). This phenotype is distinguised from LDS3 by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit aneurysms of other arteries, including abdominal aorta, iliac, and/or intracranial arteries (PubMed:21778426), they have been classified as LDS3 by the OMIM resource. .

Protein sequence and domain

The MH1 domain is required for DNA binding. Also binds zinc ions which are necessary for the DNA binding. / The MH2 domain is required for both homomeric and heteromeric interactions and for transcriptional regulation. Sufficient for nuclear import. / The linker region is required for the TGFbeta-mediated transcriptional activity and acts synergistically with the MH2 domain. / Belongs to the dwarfin/SMAD family. / Contains 1 MH1 (MAD homology 1) domain. / Contains 1 MH2 (MAD homology 2) domain.

Protein post-translational modifications

Phosphorylated on serine and threonine residues. Enhanced phosphorylation in the linker region on Thr-179, Ser-204 and Ser-208 on EGF and TGF-beta treatment. Ser-208 is the main site of MAPK-mediated phosphorylation. CDK-mediated phosphorylation occurs in a cell-cycle dependent manner and inhibits both the transcriptional activity and antiproliferative functions of SMAD3. This phosphorylation is inhibited by flavopiridol. Maximum phosphorylation at the G1/S junction. Also phosphorylated on serine residues in the C-terminal SXS motif by TGFBR1 and ACVR1. TGFBR1-mediated phosphorylation at these C-terminal sites is required for interaction with SMAD4, nuclear location and transactivational activity, and appears to be a prerequisite for the TGF-beta mediated phosphorylation in the linker region. Dephosphorylated in the C-terminal SXS motif by PPM1A. This dephosphorylation disrupts the interaction with SMAD4, promotes nuclear export and terminates TGF-beta-mediated signaling. Phosphorylation at Ser-418 by CSNK1G2/CK1 promotes ligand-dependent ubiquitination and subsequent proteasome degradation, thus inhibiting SMAD3-mediated TGF-beta responses. Phosphorylated by PDPK1. / Acetylation in the nucleus by EP300 in the MH2 domain regulates positively its transcriptional activity and is enhanced by TGF-beta. / Ubiquitinated. Monoubiquitinated, leading to prevent DNA-binding. Deubiquitination by USP15 alleviates inhibition and promotes activation of TGF-beta target genes. / Poly-ADP-ribosylated by PARP1 and PARP2. ADP-ribosylation negatively regulates SMAD3 transcriptional responses during the course of TGF-beta signaling.

Protein cellular localization

Cytoplasm / Nucleus

Research area

All research areas>Transcription Regulators>Smad
(View all antibody categories related to Transcription Regulators)


AntibodyPlus can customize Smad3 (phospho Ser204) Antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.


St John’s Laboratory Ltd.

Product type

Primary antibody


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews

There is no extra validation for this product yet.
Check other extra validated antibodies below:

Welcome to AntibodyPlus!